Redhill Biopharma Ltd experienced limited insider trading activity recently. Chief Operating Officer Gilead Raday executed a single sale valued at 1,431 USD. This transaction occurred amidst a 53.6% decline in stock price over the past ninety days, reflecting ongoing market volatility for the healthcare firm.